{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-22-000007","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.901317+00:00","generated_at":"2026-06-27T03:43:44.084452+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech reports FY2021 net loss $69.6M, cash $502.5M; on track for Vyjuvek BLA in 1H 2022","bullets":["Net loss Q4 2021 $21.8M ($0.94/share); full year $69.6M ($3.13/share) vs. $32.2M ($1.71) in 2020.","Cash & equivalents $502.5M at Dec 31, 2021, up from $271.3M; net proceeds from public offerings.","Positive Phase 3 GEM-3 data for Vyjuvek (DEB); BLA filing expected 1H 2022, MAA in 2H 2022.","Phase 1 trial of KB407 for cystic fibrosis expected to start in Australia 1H 2022; US trial in 2H 2022.","Suma Krishnan promoted to President R&D effective Feb 25, 2022; she was COO and founder."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-22-000007","json":"https://secwatch.observer/filing/0001711279-22-000007.json","markdown":"https://secwatch.observer/filing/0001711279-22-000007.md","text":"https://secwatch.observer/filing/0001711279-22-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000007/0001711279-22-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000007/krys-20220225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:43:44.084452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e960d2fbc5","claim":"Suma M. Krishnan was appointed as President, R&D at Krystal Biotech, Inc..","evidence_excerpt":"Effective February 25, 2022, the board of directors of the Company appointed Ms. Suma M. Krishnan, the Company's current Chief Operating Officer, as the Company's President, R&D.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127922000007/0001711279-22-000007-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, R&D"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}